Literature DB >> 10606789

Characterisation of the influence of micronisation on the crystallinity and physical stability of revatropate hydrobromide.

M D Ticehurst1, P A Basford, C I Dallman, T M Lukas, P V Marshall, G Nichols, D Smith.   

Abstract

Micronised particles of revatropate hydrobromide were observed to agglomerate when stored in uncontrolled conditions. Dynamic vapour sorption (DVS), isothermal microcalorimetry, microscopy and particle size measurement by laser diffraction have been used to study micronised revatropate hydrobromide. The rate and extent of agglomeration were dependent on the energy of the micronisation process, the sampling point for bulk within the mill and the humidity during storage. The agglomeration was attributed to the recrystallisation of disordered regions on the particles of revatropate hydrobromide generated during micronisation. This recrystallisation was assessed qualitatively and quantitatively, compared against spray-dried amorphous material, using DVS and isothermal microcalorimetry, respectively. A correlation was established between the energy of micronisation and the level of disorder within the micronised powder. A comparison of the DVS profiles of freshly prepared and aged micronised revatropate hydrobromide suggests an increased physical stability for the aged material.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10606789     DOI: 10.1016/s0378-5173(99)00347-6

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  10 in total

1.  Dissolution rate enhancement by in situ micronization of poorly water-soluble drugs.

Authors:  Norbert Rasenack; Bernd W Müller
Journal:  Pharm Res       Date:  2002-12       Impact factor: 4.200

2.  Anomalous particle size shift during post-milling storage.

Authors:  Wai Kiong Ng; Jin Wang Kwek; Reginald B H Tan
Journal:  Pharm Res       Date:  2007-11-29       Impact factor: 4.200

3.  Influence of excipients on physical and aerosolization stability of spray dried high-dose powder formulations for inhalation.

Authors:  Nivedita Shetty; Heejun Park; Dmitry Zemlyanov; Sharad Mangal; Sonal Bhujbal; Qi Tony Zhou
Journal:  Int J Pharm       Date:  2018-04-18       Impact factor: 5.875

4.  Structure in dehydrated trehalose dihydrate--evaluation of the concept of partial crystallinity.

Authors:  Meena Rani; Ramprakash Govindarajan; Rahul Surana; Raj Suryanarayanan
Journal:  Pharm Res       Date:  2006-08-23       Impact factor: 4.200

Review 5.  Physical stability of dry powder inhaler formulations.

Authors:  Nivedita Shetty; David Cipolla; Heejun Park; Qi Tony Zhou
Journal:  Expert Opin Drug Deliv       Date:  2019-12-13       Impact factor: 6.648

6.  Processing of spherical crystalline particles via a novel solution atomization and crystallization by sonication (SAXS) technique.

Authors:  J Sebastian Kaerger; Robert Price
Journal:  Pharm Res       Date:  2004-02       Impact factor: 4.200

7.  Liqui-Pellet: the Emerging Next-Generation Oral Dosage Form Which Stems from Liquisolid Concept in Combination with Pelletization Technology.

Authors:  Matthew Lam; Taravat Ghafourian; Ali Nokhodchi
Journal:  AAPS PharmSciTech       Date:  2019-06-24       Impact factor: 3.246

8.  Optimising the release rate of naproxen liqui-pellet: a new technology for emerging novel oral dosage form.

Authors:  Matthew Lam; Taravat Ghafourian; Ali Nokhodchi
Journal:  Drug Deliv Transl Res       Date:  2020-02       Impact factor: 4.617

9.  Production of ultrafine sumatriptan succinate particles for pulmonary delivery.

Authors:  Zong-Yang Yang; Yuan Le; Ting-Ting Hu; Zhigang Shen; Jian-Feng Chen; Jimmy Yun
Journal:  Pharm Res       Date:  2008-06-26       Impact factor: 4.580

10.  Evidence for the existence of powder sub-populations in micronized materials: aerodynamic size-fractions of aerosolized powders possess distinct physicochemical properties.

Authors:  Sara Jaffari; Ben Forbes; Elizabeth Collins; Jiyi Khoo; Gary P Martin; Darragh Murnane
Journal:  Pharm Res       Date:  2014-12       Impact factor: 4.200

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.